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Abstract
Background: Resistance to adjuvant radiotherapy is a major cause of treatment failure in patients with glioblastoma
(GBM). Autophagy inhibitors have been shown to enhance the efficacy of radiotherapy for certain solid tumors. However,
current inhibitors do not penetrate the blood-brain-barrier (BBB). Here, we assessed the radiosensitivity effects of the
antipsychotic drug trifluoperazine (TFP) on GBM in vitro and in vivo.
Methods: U251 and U87 GBM cell lines as well as GBM cells from a primary human biopsy (P3), were used in vitro
and in vivo to evaluate the efficacy of TFP treatment. Viability and cytotoxicity was evaluated by CCK-8 and clonogenic
formation assays. Molecular studies using immunohistochemistry, western blots, immunofluorescence and qPCR were
used to gain mechanistic insight into the biological activity of TFP. Preclinical therapeutic efficacy was evaluated in
orthotopic xenograft mouse models.
Results: IC50 values of U251, U87 and P3 cells treated with TFP were 16, 15 and 15.5 μM, respectively. TFP increased
the expression of LC3B-II and p62, indicating a potential disruption of autophagy flux. These results were further
substantiated by a decreased Lysotracker Red uptake, indicating impaired acidification of the lysosomes. We show
that TFP and radiation had an additive effect when combined. This effect was in part due to impaired TFP-induced
homologous recombination. Mechanistically we show that down-regulation of cathepsin L might explain the
radiosensitivity effect of TFP. Finally, combining TFP and radiation resulted in a significant antitumor effect in
orthotopic GBM xenograft models.
Conclusions: This study provides a strong rationale for further clinical studies exploring the combination therapy of
TFP and radiation to treat GBM patients.
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Background
Glioblastoma (GBM) is the most aggressive of all
intracranial tumors. Despite multimodal treatment in-
cluding surgical resection, chemotherapy and radiother-
apy, the median survival is only 14.6 months [1, 2].
Radiotherapy targets cancer cells by causing DNA damage
and is a highly cost-effective treatment [3]. However, DNA
damage induced by radiation triggers a series of signaling
cascades promoting cell survival, including DNA repair,
cell cycle arrest, and autophagy, all of which mediate
radioresistance and prevent further clinical efficacy [4].
Autophagy is a lysosome-dependent degradation and
cell survival process which represents a therapeutic tar-
get in cancer treatment due to its role in DNA damage
[5]. Several studies have shown that inhibiting autophagy
could increase the radiosensitivity of tumor cells [6–8].
Currently, multiple clinical trials have been initiated that
* Correspondence: jian.wang@uib.no; lixg@sdu.edu.cn
1Department of Neurosurgery, Qilu Hospital of Shandong University and
Brain Science Research Institute, Shandong University, Jinan 250012, People’s
Republic of China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhang et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:118 
DOI 10.1186/s13046-017-0588-z
combine conventional anti-cancer therapies with in-
hibition of autophagy [9–11]. Previous studies have
shown that Bafilomycin A1, a vacuolar H+-ATPase in-
hibitor, increases DNA degradation and significantly
increases survival after irradiation of MCF-7 (human
breast adenocarcinoma), LoVo (human colon adeno-
carcinoma), and LNCaP (human prostate carcinoma)
cells [12]. However, due to the blood-brain-barrier
(BBB), most autophagy inhibitors will not effectively
benefit GBM patients. Therefore, identifying new autoph-
agy inhibitors with improved pharmacokinetics for dis-
eases in the central nervous system (CNS) is urgently
needed.
Trifluoperazine (TFP) is a typical antipsychotic com-
pound of the phenothiazine chemical class. It has been
used in the treatment of schizophrenia for more than
50 years and relieves agitation in patients with behavioral
problems, severe nausea and vomiting as well as severe
anxiety [13]. Recently, an increasing number of studies
have found that TFP has potent anti-tumor effects in lung
cancer, malignant peripheral nerve sheath tumors and
leukemia [14–16]. Here, we examined the responses of
GBM cells to TFP in vitro and in vivo and show that TFP
inhibits autophagy by interfering with lysosome acidifica-
tion. Moreover, TFP treatment impairs DNA damage
repair following radiotherapy, providing a rationale for
combining TFP with radiation therapy in GBMs.
Methods
Cell lines
Human glioma cell lines U87 and U251 were purchased
from the cell bank of the Chinese Academy of Sciences
and were cultured in Dulbecco’s modified Eagle’s medium
(ThermoFisher Scientific; Waltham, MA, USA) containing
10% fetal bovine serum (ThermoFisher Scientific), glutam-
ine (4 mM), penicillin (10 U/mL), and streptomycin
(100 mg/mL). Normal human astrocytes (NHA) were pur-
chased from Lonza (Walkersville, MD, USA) and were
cultured in Astrocyte Medium BulletKit (Lonza) accord-
ing to the manufacturer’s instructions. P3 is a primary
GBM cell line isolated from a patient biopsy. The P3
tumor has the following molecular characteristics (+ [Chr
7, Chr19, 20q], −[1q42-q43, Chr9, Chr10, 20p] –[PIK3R1,
CDKN2A/B]. P3 cells were cultured in Neurobasal
Medium (ThermoFisher Scientific) containing penicillin
(10 U/mL), streptomycin (100 mg/mL), B27 supplement
(20 μL/mL), FGF (20 ng/mL), EGF (20 ng/mL) and
heparin (32 IE/mL).
Cell viability assay
The cytotoxic effect of TFP (Sigma; St. Louis, MO, USA)
on the GBM cell lines, P3 and NHA cells was deter-
mined using the CCK-8 assay (Dojindo; Kumamoto,
Japan). Cells were suspended in DMEM with 10% fetal
bovine serum (FBS) or Neurobasal Medium (for P3) and
seeded into 96-well, flat-bottomed plates (5 × 103 cells/
well). After incubation overnight at 37 °C, cells were pre-
treated with PBS or TFP (0–30 μM). After 24 h or 48 h
of culture, cells were incubated for an additional 2 h at
37 °C with 100 μL of serum-free DMEM or Neurobasal
Medium (for P3 cells) containing 10 μL of CCK-8, and
absorbance was measured at a wavelength of 450 nm
using a microplate reader (BioRad; Hercules, CA, USA).
EdU proliferation assay
The tumor cells (2.5 × 104 cells/well) were seeded into 24-
well, flat-bottomed plates. After 24 h, cells were treated
with PBS, 5 and 10 μM of TFP for an additional 48 h in
DMEM with 10% serum, and subsequently stained with
EdU using the Apollo Detection Kit (Ribobio; Guangzhou,
China) according to the manufacturer’s instructions. EdU
positive cells were counted from at least 10 random fields
by fluorescence microscopy (Leica DMi8; Leica Microsys-
tems, Wetzlar, Germany).
Western blot analysis
After treatment of different doses of TFP, 100 nM bafi-
lomycin A1, 2.5 μM rapamycin, 4 Gy radiation at a dose
rate of 1.8 Gy/min using a linear accelerator (Primus
Hi; Siemens Medical Instruments; Erlangen, Germany)
or 5 μM TFP for 24 h before receiving one dose of
4 Gy, whole-cell protein extracts (20-50 mg) were pre-
pared using a radioimmunoprecipitation assay buffer
(RIPA; Thermo Fisher Scientific) supplemented with
protease inhibitor cocktail (Cell Signaling Technology;
Beverly, MA, USA). Proteins were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to a polyvinylidene difluoride membrane.
Membranes were blocked with 5% skimmed milk in
Tris-buffered saline containing 0.1% Tween-20, and
subsequently incubated with primary and indicated sec-
ondary antibodies (Thermo Fisher Scientific). Proteins
on western blots where visualized using the Chemilu-
minescent Reagents Kit (Millipore, Billerica, MA, USA).
Chemiluminescent signals were detected with the Chemi-
Doc XRS+ (Bio-Rad, Hercules, CA, USA) and quantified
using Image Lab 3.0 software (Bio-Rad). The following
primary antibodies were used for western blotting: beta-
tubulin, LC3BI/II, phospho-histone H2A.X (Ser139; also
known as γ-H2A.X), P62 and survivin (Cell Signaling
Technology; Beverly, MA, USA); GAPDH, BRCA1,
BRCA2 and Rad51 were purchased from Santa Cruz
(Dallas, TX, USA).
GFP-LC3 transient transfection
Cells were transiently transfected with the pSELECT-
GFP-LC3 plasmid (Genepharma; Shanghai, China) using
Lipofectamine 2000 reagent (ThermoFisher Scientific)
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according to the manufacturer’s instructions. After being
treated with PBS or 10 μM TFP for 24 h, cells were
observed using a Leica TCS SP5 Confocal Laser Scan-
ning Microscope (Leica Microsystems) and GFP-LC3
puncta per cell was counted. Ten random fields were
obtained per treatment group.
Transmission electron microscopy
Cells were fixed in 3% glutaraldehyde in PBS for 2 h,
washed five times with 0.1 M cacodylate buffer, and post-
fixed with 1% OsO4 in 0.1 M cacodylate buffer containing
0.1% CaCl2 for 1.5 h at 4 °C. Cells were dehydrated in
graded alcohol series and embedded in epoxy resin. Ultra-
thin sections were cut and stained with uranyl acetate and
lead citrate. Images were obtained using a JEM-1200EX II
electron microscope (JEOL, Tokyo, Japan).
LysoTracker staining
Following treatment with PBS (control), 100 nM bafilomy-
cin A1 and 10 μM TFP for 48 h, U251 and U87 cells were
rinsed 3 times with fresh medium, and Lyso-Tracker Red
(diluted in DMEM with 10% FBS; ThermoFisher Scien-
tific) was added to a final concentration of 66 nM. Cells
were incubated for 30 min at 37 °C and rinsed with
phosphate-buffered saline (PBS). Nuclei were stained with
5 μg/ml Hoechst 33,342 (ThermoFisher Scientific), and
live cells were observed using a Leica DMi8 fluorescence
microscope.
Comet assay (single cell gel electrophoresis assay)
Comet assays were performed according to a previously
described protocol [17]. Briefly, after treatment with PBS,
TFP, radiation or combination treatment, cells were thor-
oughly mixed with low melting point agarose solution.
Radiation treatment was carried out with a single dose of
4 Gy at a dose rate of 1.8 Gy/min using a linear acceler-
ator (Primus Hi). The cell suspension was spread on a
Comet Slide (CometAssay® Kit, Trevigen; Gaithersburg,
MD, USA) covered with 1.5% normal melting agarose.
Slides were immersed in prepared lysis solution, treated
with Tris-EDTA buffer (10 mM TrisCl, pH 7.5, 1 mM
EDTA), and then placed horizontally on an electrophor-
esis tray filled with alkaline solution (300 mM NaOH,
1 mM EDTA). Electrophoresis was conducted at room
temperature with an electrical field of 25 V and a current
of 300 mA for 20 min. After electrophoresis, the slides
were stained with GelRed (Biotium; Fremont, CA, USA).
Slides were examined under fluorescence microscopy.
Cells were analyzed using the Comet Assay Software
Project (CASP). Olive tail moment (OTM) was used to
quantify the extent of DNA damage.
Immunofluorescence
Immunofluorescence detection of γ-H2A.X foci was per-
formed to monitor formation of DNA double strand
breaks (DSBs). Cells cultured on coverslips were treated
with PBS or 5 μM of TFP before receiving one dose of
4 Gy at a dose rate of 1.8 Gy/min using a linear acceler-
ator (Primus Hi). At indicated time points (2, 6, 12 and
24 h), the cells were rinsed with PBS and then fixed in 4%
paraformaldehyde before permeabilisation with 0.3% Tri-
ton X-100. After blocking with 5% BSA (Sigma), cells were
incubated with diluted primary antibody for γ-H2A.X
overnight at 4 °C, followed by staining with Fluorescein
(FITC)-conjugated goat anti-rabbit IgG (ThermoFisher
Scientific). Finally, the samples were mounted in mount-
ing medium containing DAPI (ThermoFisher Scientific).
Three random fields were examined at a magnification of
×63 by a Leica TCS SP5 Confocal Laser Scanning
Microscope.
Colony formation assay
U251 and U87 cells (3 × 103 cells/well) were plated in
six-well plates. The adherent cells were then treated with
PBS or 5 μM TFP for 24 h before receiving one dose of
4 Gy at a dose rate of 1.8 Gy/min whereupon they were
incubated for 14 days. Then colonies were washed with
PBS, fixed in 4% paraformaldehyde, stained with 0.1%
crystal violet and counted. Colonies consisting of more
than 50 cells were counted as surviving colonies.
Apoptosis analysis
Apoptosis was measured by quantifying cleaved-caspase 3
and 7 activity using Cell Event Caspase 3/7 Green Detec-
tion Reagent (Life Technologies, Carlsbad, CA, USA).
Cells were plated in 96-well plates with a density of 3000
cells per well and allowed to adhere. Thereafter, the cells
were treated with PBS or 5 μM TFP for 24 h before receiv-
ing one dose of 4 Gy at a dose rate of 1.8 Gy/min in a lin-
ear accelerator (Primus Hi). Then the cells were inspected
using an IncuCyte Zoom live cell imaging system (Essen
BioScience, Ann Arbor, MI, USA).
Homologous recombination (HR) assay
An HR assay (Norgen Biotek, Thorold, ON, Canada)
was performed on U251 and U87 cells according to
manufacturer’s instructions. Briefly, at day 3 after TFP
treatment, cells were transfected with a positive control
plasmid or two HR dl plasmids (dl-1 and dl-2). After
24 h of transfection, DNA was isolated using the Wizard
genomic DNA purification kit (Promega, Madison, WI,
USA). qPCR was performed with the supplied primers
using a Roche LightCycler 480 II (Roche Applied
Science, Indianapolis, IN, USA).
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Cathepsin B and L activity
Activity of cathepsin B and L in U251 and U87 cells was
tested using a Fluorometric Assay Kit (Abcam, Cambridge,
UK) according to the manufacturer instructions. Briefly,
after treatment with PBS (control) or 5 μM TFP for 24 h,
the cells were lysed and supernatants were incubated with
cathepsin-B (Ac-RR-AFC) or L (AC-FR-AFC) substrates
at 37 °C for 1.5 h. Then samples were measured on a
fluorescent microplate reader at excitation/emission
wavelength = 400/505 nm. After subtracting the back-
ground control (buffer) from sample readings, activity
of cathepsin B and L was determined by comparing
results from TFP treated cells with the level from
controls.
Transfection of siRNA
U251 and U87 cells were transfected with siRNA twice at
a 24-h interval with lipofectamine 2000. The final concen-
tration of siRNAs was 50 nM. Sequences for the siRNAs
used were the following: cathepsin L, 5′-GATGCACAAC
AGATTATACTT-3′; nontargeting siRNA controls, 5′-UU
CUCCGAACGUGUCACGUTT-3′ (Genepharma). Western
blot analysis was used to assess the downregulation of
cathepsin L.
Intracranial implantation and drug therapy
All animal protocols were approved by the ethics com-
mittee at the Shandong University (Jinan, China) and
conducted according to the national regulations in
China. For implantations, nude mice were anesthetized
with 4% chloral hydrate (300 mg/kg) and placed in a
stereotactic frame. Using aseptic surgical procedures, an
incision was made in the parietal scalp, and a small burr
hole was drilled 2.5 mm lateral to the bregma. U251 and
P3 cells (1 × 106 cells/mouse) were implanted 2.0 mm
into the right striatum using a Hamilton syringe
(Hamilton Co., Reno, NV, USA). Two weeks later, mice
were randomly divided into four groups (6 mice/group).
Groups 1 and 2 were injected intraperitoneally (IP) with
PBS or TFP (1 mg/kg, 5 days/week). Group 3 was given
three doses of localized irradiation (5 Gy) at days 15, 20,
and 25 after implantation following IP injection of PBS.
Group 4 was irradiated three times following IP injection
of TFP. Mice were sacrificed when central nervous
system symptoms (such as poor ambulation, lethargy,
hunched posture) or weight loss > 20% body mass devel-
oped. The mice were anesthetized with chlorohydrate
and perfused transcardially with 4% paraformaldehyde in
PBS. Whole brains were removed, post-fixed overnight
in 4% paraformaldehyde in PBS, coronally sectioned into
5 slices, and paraffin embedded. Tissue sections were
cut (10 μm) and incubated with primary antibodies as
indicated. The following primary antibodies were used
for immunohistochemistry: Ki67 (Abcam); γ-H2A.X
(Cell Signaling Technology), and Rad51 (Santa Cruz).
Statistical analysis
Unpaired T-tests were performed using SPSS software
13.0 (SPSS Inc., Chicago, IL). Results are presented as the
mean ± SE. P-values <0.05 were considered statistically
significant.
Results
TFP inhibits GBM cell growth in vitro
The cytotoxic effects of TFP on tumor cells in vitro were
determined using the CCK-8 assay (Fig. 1a, b). The IC50
values of TFP for U251, U87 and P3 cells were 16 μM,
15 μM, 15.5 μM, respectively. GBM cells were significantly
more sensitive to TFP compared to normal human astro-
cytes (IC50 22.5 μM, P < 0.05). These results were further
substantiated by the use of a proliferation assay where
EdU was incorporated in U251 and U87 cells. The
number of EdU positive cells decreased in a dose
dependent manner in both cell populations (Fig. 1c, d).
These results were further confirmed by a reduced clo-
nogenic ability and increased caspase activity following
TFP treatment (Fig. 5c, d).
TFP interferes with autophagy flux in GBM cells
Previous studies have suggested that TFP induces
autophagy [18]. LC3B, a membrane component of autop-
hagosomes, is used as a marker for the induction of
autophagy. Analyses of LC3B by western blot showed in-
creased levels after upon TFP treatment (Fig. 2a). To
visualize the development of autophagosomes following
TFP treatment, we transiently transfected GBM cells with
a GFP-LC3 expression construct. Confocal microscopy
showed an increase in fluorescence puncta in TFP treated
cells after 24 h (Fig. 2b). Transmission electron microscopy
(TEM) represents the gold standard for detecting autopha-
gic vacuoles (AVs). More AVs were detected in TFP treated
cells compared to the control group (Black arrows, Fig. 2c).
Autophagy is a dynamic multistage process where the
assembly of autophagosomes is an early event. The assem-
bly of autophagosomes is therefore not directly connected
to autophagosome degradation. Thus, an accumulation of
AVs in cells can occur either as a consequence of an in-
creased autophagosome formation or decreased degrad-
ation [19]. The levels of SQSTM/p62, one of the most
important long-lived proteins critical for autophagy, accu-
mulated in a dose-dependent manner in response to TFP
(Fig. 2d). This indicates that TFP blocks autophagy.
Rapamycin, which induces autophagy by inhibition of
mTOR [20], and Bafilomycin A1 (BAF), which blocks
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autophagy by selectively inhibiting H+-ATPase [21],
were used as positive controls. Our results show that
p62 levels decreased in rapamycin treated cells
whereas it was clearly increased in cells treated with
TFP or BAF (Fig. 2e).
BAF blocks autophagy flux by reducing the acidifica-
tion of lysosomes. Altered lysosome function prevents
fusion of autophagosomes with lysosomes. LysoTracker
Red, which labels highly acidic lysosomal vacuoles and
thus detects activity of vacuolar H+-ATPase (v-ATPase)
[22], was used to determine the status of lysosomes after
TFP or BAF treatment. Under fluorescence microscopy,
lysosomes could not be detected with LysoTracker Red
in TFP and BAF treated cells (Fig. 3a). These results
indicate that TFP blocks autophagy by inhibiting the
acidification of lysosomes.
TFP enhances the radiosensitivity of GBM cells
A number of studies have demonstrated that inhibitors of
autophagy enhance the sensitivity of cells to radiation
therapy [6, 8, 23]. To investigate whether TFP affected ra-
diosensitivity, we used the comet assay to measure DNA
integrity in U251 and U87 cells. TFP or radiation treat-
ment alone slightly increased the levels of DNA tails above
controls, whereas combined treatment caused a significant
increase in the appearance of DNA tails (Fig. 3b, c).
Protein levels of γ-H2AX, a gold standard to detect the
Fig. 1 TFP inhibited GBM cell growth in vitro. a and b Cell viability of U251, U87, P3 and NHA as determined in CCK8 assays after treatment with
TFP for 24 or 48 h. c Fluorescence microscopy of EdU assays after treatment of U251 and U87 cell lines with TFP at concentrations of 0, 5, and
10 μM. d Quantification of EdU assays. *P < 0.05; **P < 0.01; size bars = 50 μm
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presence of DSBs [24], were correspondingly increased
following combination treatment (Fig. 3d).
TFP increases radiosensitivity by impairing homologous
recombination repair
We next quantified γ-H2AX foci at different time points
after radiation treatment or TFP combined with radiation
using immunofluorescence. Radiation induced more γ-
H2AX foci after 2 h of treatment. This was reduced con-
siderably from 6 h and onwards. However, TFP treatment
resulted in a significant prolongation of the γ-H2AX signal
at least 24 h post irradiation in U251 and U87 cells (27%
and 21.6%, respectively) compared with radiation alone
(10%, P < 0.01; 2.3%, P < 0.05. Figure 4a, b). Radiation
induces apoptosis mainly by generating DSBs. DSBs can
be repaired by either non-homologous end joining (NHEJ)
or homologous recombination (HR). In NHEJ, ligation
occurs regardless of whether the ends come from the
same chromosome. Thus loss of genetic information and
translocations might occur [25]. HR uses the information
that is contained in genetically identical, or almost identi-
cal, DNA molecules (usually the sister chromatid) to re-
pair damaged DNA, and therefore, has a higher accuracy
of maintaining DNA integrity [26]. The DNA repair pro-
tein Rad51 polymerizes onto resected DNA ends to form
a nucleoprotein filament and promotes strand exchange
between homologous DNA duplexes. As such, Rad51
plays a central role in HR and is crucial for the stability of
the genome and the normal cell cycle [27]. After treat-
ment of TFP, we found that the expression of Rad51 and
the associated DNA repair proteins BRCA1 and BRCA2,
decreased, while γ-H2AX increased in a dose-dependent
manner (Fig. 5a). In addition, HR efficiency was calculated
using a PCR-based HR assay kit. We found that after TFP
Fig. 2 TFP interrupts autophagy flux of GBM cells. a Western blot showing expression of LC3BI/II in U251 and U87 cells incubated for 24 h with
TFP at increasing concentrations. b Images of LC3 puncta in GBM cells transfected with pSELECT-GFP-LC3 and treated with PBS and 10 μM TFP
for 48 h. c Images from transmission electron microscopy showing characteristic autophagic vacuoles (Black arrows) in GBM cells after treatment
with PBS or 10 μM TFP for 48 h. d and e Western blot showing p62 levels in GBM cells after treatment with increasing concentrations of TFP,
100 nM bafilomycin A1, 2.5 μM rapamycin and 10 μM TFP for 48 h. **P < 0.01; ***P < 0.001; size bars in b = 10 μm, size bars in c = 1 μm
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treatment, the HR efficiency decreased significantly
(P < 0.05) compared to the control group (Fig. 5b).
TFP might therefore lead to an increase in DSBs and
radiosensitivity by inhibiting the expression of central
DNA repair proteins.
Down-regulating cathepsin L might contribute to the
radiosensitivity effect of TFP
Lysosomes play an important role during autophagy and
among all the lysosomal proteases, cathepsins have mul-
tiple roles, not only in the degradation of nonfunctional
organelles, but also in the process of tumorigenesis [28].
Earlier studies have also shown that proteasomes as well
as lysosomes can contribute to cellular tolerance to vari-
ous proteotoxic stressors, and confer resistance to
chemo-, radio- and immunotherapy [29]. We therefore
wanted to assess a putative role of lysosomes as a link
between autophagy and DNA damage repair following
TFP treatment. Moreover, impaired acidification of lyso-
somes might affect the activity of cathepsins, which is
optimized for low pH [30]. We first examined the en-
zymatic activities of two main cathepsins (B and L), in
Fig. 3 TFP influences the acidification of lysosomes and increases the radiosensitivity of GBM cells. a LysoTracker Red in cells after treatment with
PBS, 100 nM bafilomycin A1 and 10 μM TFP for 48 h. Nuclei are stained with Hoechst. b and c Comet assays to evaluate DNA damage in cells
after treatment with PBS, 5 μM TFP, or 4 Gy radiation for 48, or pretreated with 5 μM TFP for 24 h combined with 4 Gy radiation and TFP for
another 24 h. d Western blot for γ-H2AX in GBM cells after treatment. **P < 0.01; size bars = 50 μm
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response to TFP. With a fluorometric-based kit, we
found that after TFP treatment, the activity of cathepsin
B and L decreased significantly (Fig. 6a). By western blot
analysis, we also found that cathepsin B heavy chain (the
mature form of cathepsin), procathepsin B and cathepsin
L decreased in a dose-dependent manner (Fig. 6b).
Previous studies have shown that cathepsin L is not only
involved in autophagy [31–33], but also in radioresis-
tance [34, 35]. After knocking down cathepsin L, we
found that the expression of P62 and γ-H2AX increased,
while Rad51 decreased (Fig. 6c), which was in consistent
with the results observed after TFP treatment. Finally,
HR efficiency also decreased significantly after knocking
down cathepsin L (Fig. 6d). In conclusion, these data
suggest that down-regulation of cathepsin L might
explain the radiosensitivity effect of TFP.
Combining TFP and radiotherapy treatment enhances
survival
To evaluate the antitumor effect of TFP in combination
with radiation in vivo, we established orthotopic xeno-
graft models with U251 and P3 cells (Fig. 7a). The
survival curves demonstrated no survival benefit from
radiation treatment alone (median survival 24.8 and
29.7 days, −control vs radiation respectively, P > 0.05),
while TFP significantly prolonged survival (median
survival 24.8 days vs 33.8 days, control vs TFP respect-
ively). Combined treatment with TFP and radiation signifi-
cantly increased the overall median survival of animals
and produced some long-term survivors (median survival
46 days vs 29.7 days, radiation vs combined treatment,
P < 0.01; median survival 46 days vs 33.8 days, TFP vs
combined treatment, P < 0.05. Fig. 7b). Analyses of Ki67
positive cells by immunohistochemistry from TFP treated
sections and the combination group showed a dramatic
decrease in tumor cell proliferation compared to the con-
trol and radiation group (Fig. 7c). Sections stained for γ-
H2AX and Rad51 showed that in the TFP treatment
group, the expression of Rad51 decreased compared
with controls while in the radiation treatment group
it was increased. In the combined treatment group, a
significantly reduced fraction of cells was positive for
Rad51 compared to controls. Animals treated with
TFP and radiation displayed a significant increase in
γ-H2AX staining compared with either treatment
alone (Fig. 7c). In summary, our data demonstrates
that TFP sufficiently penetrates the BBB and increases
radiosensitivity in vivo.
Fig. 4 TFP decreases DNA damage repair in GBM cells. a and b Immunofluorescence for γ-H2AX at different time points after irradiation in GBM
cells treated with PBS or TFP. *P < 0.05; **P < 0.01; ***P < 0.001; size bars = 10 μm
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Discussion
Recent research has shown that autophagy has a cyto-
protective effect during anticancer therapy with DNA-
damaging agents. It has also been shown that autophagy
inhibition can sensitize tumor cells to such agents [8, 36].
In general, the cytoprotective function of autophagy
appears to be linked to apoptosis inhibition through a
cross-talk between autophagy and apoptosis regulatory
pathways [4]. Therefore, clinical trials have been initiated
combining autophagy inhibitors with traditional radio-
chemotherapy for the treatment of GBMs [9–11]. How-
ever, due to a limited BBB penetration, many autophagy
inhibitors do not reach effective concentrations within the
brain, −or the dosage is so high that it causes serious side
effects. Therefore, novel autophagy inhibitors that can
effectively enter the brain are urgently needed.
Drug repurposing has gained increased attention since
these drugs have documented safety profiles from clinical
use. It is well known that established drugs may have
other mechanisms of action beyond the purpose for which
they were developed. Drug repositioning also overcome,
to a large extent, problems related to laborious and ex-
pensive drug development processes [37]. Furthermore,
the development of many compounds runs into issues
related to safety. Although known as an autophagy
inducer [38, 39], an increasing number of studies have
illustrated that TFP shows therapeutic efficacy towards
various neoplasms, such as lung cancer, malignant per-
ipheral nerve sheath tumors, and leukemia [14–16].
Here, we show that TFP inhibits GBM growth in vitro
and in vivo. Mechanistically we show that TFP inter-
rupts autophagy flux by inhibiting the acidification of
lysosomes.
Radiation therapy combined with temozolomide (TMZ)
treatment represents the standard treatment of care for
GBM patients. However, therapeutic efficacy is significantly
Fig. 5 TFP decreases HR repair and causes synergistic anticancer effect with radiation in GBM cells. a Western blots for Rad51, BRCA1, BRCA2 and
γ-H2AX in U251 and U87 cells after different doses of TFP treatment. b HR activity of U251 and U87 after treatment of PBS and 5 μM
TFP. c Colony formation of U251 and U87 after treatment with PBS, 5 μM TFP, or 4 Gy radiation for 48 h, or pretreated with 5 μM TFP
for 24 h combined with 4 Gy radiation and TFP for another 24 h. d Caspase 3/7 activation of GBM cells in four treatment groups.
**P < 0.01; ***P < 0.001; size bars = 50 μm
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limited by the development of tumor resistance mecha-
nisms, both towards radiation therapy and TMZ. Radiore-
sistance can develop by multiple factors mediated by the
tumor cells as well as by the microenvironment [40]. DNA
damage repair is an essential mechanism that is triggered
in cells for maintaining genetic integrity, −in order to
survive potentially lethal levels of DNA damage. Among all
the factors involved in DNA damage repair, HR plays the
most prominent role. Early studies have shown that mul-
tiple immortalized, tumor cell lines and primary tumor
samples overexpress Rad51 [41, 42]. These studies have
implicated Rad51 in oncogenesis and indicate that tumor
cells show extreme capabilities to repair DNA damage
caused by chemotherapy and radiotherapy. In the present
work, we show that TFP decreases the expression of the
HR proteins Rad51, BRCA1 and BRCA2, followed by
increased DNA damage. This indicates that HR efficiency
is attenuated during TFP treatment.
In our study, we find that TFP impairs lysosome acidifi-
cation. Lysosomal proteases, especially cathepsins play an
important role in late stage of autophagy [28, 32]. Some
studies also demonstrate that cathepsin L contributes to
the radioresistance of GBM cells [34, 35]. We show here
that the activity as well as protein levels of cathepsin L
decreases significantly after TFP treatment. Moreover,
western blot analysis shows that cathepsin L silencing in-
creases P62 and γ-H2AX, whereas Rad51 is decreased.
Also, knock-down of cathepsin L led to a decreased HR
efficiency. These results suggested that TFP might achieve
a radiosensitivity effect by down-regulating cathepsin L.
Therefore, cathepsin L might be an important factor in
the regulation of autophagy, DSBs, and DNA damage
repair, which makes it an attractive target in the radiosen-
sitization of GBM.
The BBB is a major impediment to the entry of many
drugs into the brain, partly because drugs that are P-
glycoprotein (P-gp) substrates are extruded from the brain
by the BBB [43]. Studies have shown that TFP inhibits the
expression of P-gp [44], which may lead to effective drug
concentrations within the brain and also GBMs.
In addition, TFP is also indicated for use in agitation,
and in patients with behavioral problems as well as
severe anxiety, severe nausea and vomiting, which may
improve patients’ symptoms after surgery and radiation
therapy. Thus, TFP might provide GBM patients with a
better life quality during treatment. Given the long clin-
ical use of TFP in psychotic and non-psychotic patients
since the late 1950s, we provide a strong rationale for
using TFP for the treatment of GBM patients together
with standard therapy.
Fig. 6 Cathepsin L links autophagy and DNA damage repair to the radiosensitivity effect of TFP. a Activity of cathepsin B and L after treatment
with PBS (control) and 5 μM TFP. b Western blot analysis of cathepsin B heavy chain, procathepsin B and cathepsin L after different TFP treatment
doses (0-10 μM). c Western blots for cathepsin L, P62, Rad51 and γ-H2AX in U251 and U87 cells before and after cathepsin L knock-down. d HR activity
of U251 and U87 before and after cathepsin L knock down. **P < 0.01; ***P < 0.001
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Conclusion
In conclusion, the present study revealed a new potential
mechanistic insight into the radiosensitization induced
by TFP. In our system, TFP treatment effectively de-
creased the expression of Rad51, BRCA1, BRCA2 and HR.
Also, combining TFP and radiation resulted in a signifi-
cant antitumor effect in orthotopic GBM xenograft
models in vivo. This study therefore provides the basis for
clinical studies combining TFP and radiation.
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